| Frank G Maben, DPM | |
|
270 W Chandler Heights Rd Ste 5, Chandler, AZ 85248-5084 | |
| (480) 895-0276 | |
| (480) 895-6933 |
| Full Name | Frank G Maben |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 20 Years |
| Location | 270 W Chandler Heights Rd Ste 5, Chandler, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013078120 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 0649 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bhsm Rehabilitation Llc | 2062773138 | 1258 |
| Ocotillo Foot And Ankle Centers, Pllc | 9436493376 | 3 |
News Archive
Combining a new class of drug with two other compounds can significantly shrink lung tumors in mice and human cancer cells, finds a new study led by the Francis Crick Institute and The Institute of Cancer Research, London.
Telemedicine is changing the way patient care is provided in a growing number of intensive care units (ICUs) across the country, and tele-ICU nurses - who see its impact firsthand - say it provides an opportunity to improve care, according to results of a national survey published in the American Journal of Critical Care.
Of high-risk therapeutic devices approved via the Food and Drug Administration Premarket Approval (PMA) pathway between 2010 and 2011, there has been wide variation in both the number and quality of premarket and postmarket studies, with approximately 13 percent of initiated postmarket studies completed between 3 and 5 years after FDA approval, according to a study in the August 11 issue of JAMA.
Dr. Jayakrishna Ambati UK HealthCare physician and Associate Professor and Vice Chair of the Department of Ophthalmology and Visual Sciences, announced a discovery by his research team that will impact how physicians and patients approach treatment for macular degeneration.
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products.
› Verified 8 days ago
| Provider Name | Ocotillo Foot And Ankle Centers, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1356824759 PECOS PAC ID: 9436493376 Enrollment ID: O20181204003104 |
News Archive
Combining a new class of drug with two other compounds can significantly shrink lung tumors in mice and human cancer cells, finds a new study led by the Francis Crick Institute and The Institute of Cancer Research, London.
Telemedicine is changing the way patient care is provided in a growing number of intensive care units (ICUs) across the country, and tele-ICU nurses - who see its impact firsthand - say it provides an opportunity to improve care, according to results of a national survey published in the American Journal of Critical Care.
Of high-risk therapeutic devices approved via the Food and Drug Administration Premarket Approval (PMA) pathway between 2010 and 2011, there has been wide variation in both the number and quality of premarket and postmarket studies, with approximately 13 percent of initiated postmarket studies completed between 3 and 5 years after FDA approval, according to a study in the August 11 issue of JAMA.
Dr. Jayakrishna Ambati UK HealthCare physician and Associate Professor and Vice Chair of the Department of Ophthalmology and Visual Sciences, announced a discovery by his research team that will impact how physicians and patients approach treatment for macular degeneration.
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Frank G Maben, DPM 270 W Chandler Heights Rd Ste 5, Chandler, AZ 85248-5084 Ph: (480) 895-0276 | Frank G Maben, DPM 270 W Chandler Heights Rd Ste 5, Chandler, AZ 85248-5084 Ph: (480) 895-0276 |
News Archive
Combining a new class of drug with two other compounds can significantly shrink lung tumors in mice and human cancer cells, finds a new study led by the Francis Crick Institute and The Institute of Cancer Research, London.
Telemedicine is changing the way patient care is provided in a growing number of intensive care units (ICUs) across the country, and tele-ICU nurses - who see its impact firsthand - say it provides an opportunity to improve care, according to results of a national survey published in the American Journal of Critical Care.
Of high-risk therapeutic devices approved via the Food and Drug Administration Premarket Approval (PMA) pathway between 2010 and 2011, there has been wide variation in both the number and quality of premarket and postmarket studies, with approximately 13 percent of initiated postmarket studies completed between 3 and 5 years after FDA approval, according to a study in the August 11 issue of JAMA.
Dr. Jayakrishna Ambati UK HealthCare physician and Associate Professor and Vice Chair of the Department of Ophthalmology and Visual Sciences, announced a discovery by his research team that will impact how physicians and patients approach treatment for macular degeneration.
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products.
› Verified 8 days ago
Eric Chen, Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1831 E Queen Creek Rd, Chandler, AZ 85286 Phone: 480-216-4395 | |
Chase Alexander Corley, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1831 E Queen Creek Rd, Chandler, AZ 85286 Phone: 480-917-2300 | |
Dr. Edward William Tierney, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3042 W. Queen Creek Road, Chandler, AZ 85248 Phone: 520-796-2600 Fax: 520-795-2666 | |
Floyd I Miller, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2175 N Alma School Rd Ste C109, Chandler, AZ 85224 Phone: 480-545-2610 Fax: 480-545-2673 | |
Dr. Michael Hansol Ham Jr., DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1831 E Queen Creek Rd, Chandler, AZ 85286 Phone: 480-917-2300 | |
Dr. Alan J Discont, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 600 S Dobson Rd, Suite D35, Chandler, AZ 85224 Phone: 480-732-0033 Fax: 480-732-0038 |